N-Power Medicine has secured initial funding in a Series B round, boosting its total funding to $72 million. Led by Merck Global Health Innovation Fund, the investment will fuel the expansion of N-Power’s unique platform that seamlessly integrates clinical trials into routine patient care.
N-Power’s groundbreaking platform offers a single workflow for clinical trials and patient management, eliminating inefficiencies and increasing accessibility for oncologists and patients. Leveraging AI-enabled automation and on-site support empowers healthcare providers to generate research-ready data and prepare standardized documentation.
Mark Lee, N-Power CEO, indicated that their mission is to dramatically reduce drug development time by making clinical research readily accessible to all oncologists and cancer patients. This model will ultimately benefit patients by providing faster access to innovative therapies.
The N-Power platform encompasses three key components:
•Integrated Data Platform: This single platform streamlines data collection for clinical trials and routine patient care.
•Human-in-the-Loop Model: Virtual and on-site staff, assisted by AI, support oncologists in data collection and documentation, freeing up their time for patient care.
•Kaleido Registry: This registry includes over 7,000 patients, providing a wealth of data for trial design and real-time identification of eligible patients.
David Rubin, Managing Director of Merck Global Health Innovation Fund, suggested that N-Power offers a transformative approach to clinical research by expanding access and providing actionable insights.
By embracing N-Power’s platform, oncologists can overcome challenges such as electronic medical record management and clinical trial recruitment. Patients benefit from greater access to clinical trials and standardized care.
N-Power’s mission is to revolutionize drug development by unlocking the potential of real-world data, enabling biopharmaceutical companies to develop therapies faster and with greater patient impact.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
